Chris Parker

25.8k total citations · 5 hit papers
245 papers, 11.2k citations indexed

About

Chris Parker is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Chris Parker has authored 245 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Pulmonary and Respiratory Medicine, 112 papers in Radiology, Nuclear Medicine and Imaging and 53 papers in Oncology. Recurrent topics in Chris Parker's work include Prostate Cancer Treatment and Research (185 papers), Prostate Cancer Diagnosis and Treatment (103 papers) and Radiopharmaceutical Chemistry and Applications (86 papers). Chris Parker is often cited by papers focused on Prostate Cancer Treatment and Research (185 papers), Prostate Cancer Diagnosis and Treatment (103 papers) and Radiopharmaceutical Chemistry and Applications (86 papers). Chris Parker collaborates with scholars based in United Kingdom, United States and Canada. Chris Parker's co-authors include Alan Horwich, David P. Dearnaley, Mark Emberton, Hashim U. Ahmed, Richard Kaplan, Louise Brown, Rhian Gabe, Ahmed El‐Shater Bosaily, Richard Hindley and Mahesh Parmar and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chris Parker

240 papers receiving 11.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

2017 2.2k citations Louise Brown, Mahesh Parmar et al. profile →
Prostate cancer

2015 708 citations Gerhardt Attard, Chris Parker et al. profile →
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 577 citations Chris Parker, Elena Castro et al. Annals of Oncology profile →
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010 487 citations Alan Horwich, Chris Parker et al. Annals of Oncology profile →
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 297 citations Chris Parker, Silke Gillessen et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Chris Parker	8.5k	3.3k	2.5k	1.7k	1.6k	245	11.2k
Bertrand Tombal	10.9k 1.3×	3.4k 1.0×	3.2k 1.3×	2.6k 1.5×	1.8k 1.1×	459	14.2k
Robert E. Reiter	7.6k 0.9×	2.7k 0.8×	2.8k 1.1×	2.0k 1.2×	3.6k 2.3×	234	12.0k
Thomas Wiegel	8.2k 1.0×	1.7k 0.5×	1.8k 0.7×	1.1k 0.6×	838 0.5×	232	10.5k
Nicolas Mottet	6.8k 0.8×	1.4k 0.4×	1.6k 0.6×	991 0.6×	983 0.6×	147	8.6k
Arnauld Villers	10.4k 1.2×	2.9k 0.9×	1.2k 0.5×	944 0.6×	1.1k 0.7×	339	12.8k
Misop Han	9.9k 1.2×	1.0k 0.3×	1.7k 0.7×	1.7k 1.0×	1.7k 1.0×	225	12.1k
R. Jeffrey Karnes	8.5k 1.0×	1.1k 0.3×	2.0k 0.8×	2.4k 1.4×	2.3k 1.4×	428	12.4k
Phillip D. Stricker	5.6k 0.7×	1.9k 0.6×	1.1k 0.5×	979 0.6×	1.4k 0.9×	187	8.2k
Kurt Miller	9.1k 1.1×	2.7k 0.8×	2.9k 1.2×	3.5k 2.1×	4.6k 2.9×	358	14.7k
Thomas J. Polascik	6.6k 0.8×	1.7k 0.5×	1.0k 0.4×	834 0.5×	2.0k 1.2×	341	9.2k

Countries citing papers authored by Chris Parker

Since Specialization

Citations

This map shows the geographic impact of Chris Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Parker more than expected).

Fields of papers citing papers by Chris Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Parker. The network helps show where Chris Parker may publish in the future.

Co-authorship network of co-authors of Chris Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Parker. A scholar is included among the top collaborators of Chris Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Parker. Chris Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parker, Chris, et al.. (2024). Sustainability and affordability of building electrification: A state-by-state holistic approach for multifamily buildings. Sustainable Cities and Society. 109. 105515–105515. 1 indexed citations

Patel, Priyanka, Alison Reid, Chris Parker, et al.. (2024). Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial. Clinical Oncology. 36(9). 585–592. 2 indexed citations

Parker, Chris, Noel W. Clarke, Adrian Cook, et al.. (2024). Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). European Urology. 86(5). 422–430. 5 indexed citations

Sundahl, Nora, Douglas Brand, Chris Parker, et al.. (2024). Weekly ultra-hypofractionated radiotherapy in localised prostate cancer. Clinical and Translational Radiation Oncology. 47. 100800–100800. 2 indexed citations

Murphy, Laura, Macey L. Murray, Louise Brown, et al.. (2023). 1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison. Annals of Oncology. 34. S963–S963. 4 indexed citations

Parker, Chris, Nina Tunariu, Holly Tovey, et al.. (2023). Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. JNCI Cancer Spectrum. 7(6). 3 indexed citations

Attard, Gerhardt, Louise Brown, Nigel Clarke, et al.. (2021). LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology. 32. S1298–S1298. 5 indexed citations

Parker, Chris, Elena Castro, Karim Fizazi, et al.. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 31(9). 1119–1134. 577 indexed citations breakdown →

Meisel, Alexander, et al.. (2020). 637P The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial. Annals of Oncology. 31. S524–S525. 2 indexed citations

10.

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations

11.

Brand, Douglas, David P. Dearnaley, Rosalind A. Eeles, et al.. (2019). Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and Oncology. 141. 174–180. 15 indexed citations

12.

Verbeek, Jan, Daan Nieboer, Chris Parker, et al.. (2019). A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. Journal of Personalized Medicine. 9(2). 19–19. 1 indexed citations

13.

Wilkins, Anna, Shama Hassan, Claire Blanchard, et al.. (2018). Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. Clinical and Translational Radiation Oncology. 10. 1–6. 1 indexed citations

14.

Parker, Chris, Nicholas D. James, Chris Brawley, et al.. (2018). Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE. Annals of Oncology. 29. viii722–viii723. 1 indexed citations

15.

Amadori, D., Claudio Rossetti, Massimo Aglietta, et al.. (2015). 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. Annals of Oncology. 26. vi54–vi54. 4 indexed citations

16.

Rossetti, Claudio, Massimo Aglietta, Caterina Messina, et al.. (2015). External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. Annals of Oncology. 26. vi61–vi61. 3 indexed citations

17.

Parker, Chris, Daniel Heinrich, David Bottomley, et al.. (2013). Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases. European Journal of Cancer. 49. 2 indexed citations

18.

Parker, Chris, et al.. (2009). Treatment of early prostate cancer: active surveillance. 14(3). 15–19. 2 indexed citations

19.

Horwich, Alan, Chris Parker, & Vesa Kataja. (2009). Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 20. iv76–iv78. 29 indexed citations

20.

Parker, Chris, Mary Gospodarowicz, & Padraig Warde. (2001). Does age influence the behaviour of localized prostate cancer?. British Journal of Urology. 87(7). 629–637. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact